Tirzepatide has emerged as a groundbreaking therapy for Wegovy manufacturer type 2 diabetes, offering promising outcomes. However, the cost of this innovative drug and its access have become key issues for patients and healthcare providers. While tirzepatide has been approved by regulatory agencies, its costly nature presents a significant obstacl